EUVIMEDEUVIMED entdecken
Crossref

Comparison of Receptor Profiles Between Primary Tumors and Isolated Thoracic Metastasesin Breast Cancer

Aybiyçe E. SİLPAĞAR, Eyüp Halit Yardımcı, Mehmet Yıldırım

Revista do Grupo de Estudos do Cancro do Pulmão · 11.05.2026

DOI: 10.82582/thorac.95 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista do Grupo de Estudos do Cancro do Pulmão, erschienen am 11.05.2026. Verfasst von Aybiyçe E. SİLPAĞAR und 2 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Receptor status may change during metastatic progression, potentially altering therapeutic decisions and outcomes. This study aimed to determine ER, PR, and HER2 changes in thoracic metastases (pleura, lung, lymph node, pericardium, chest wall) of breast cancer and to evaluate their impact on survival.

Methods

Data of 46 women who underwent an interventional procedure for thoracic metastasis of breast cancer and had available ER/PR/HER2 assessment in both primary and corresponding metastatic tissues were retrospectively analyzed. Post-metastasis survival was calculated from the date of histopathological confirmation of metastatic disease. The associations of primary breast cancer receptor status, metastatic receptor status, and receptor conversion at metastasis with survival outcomes were investigated.

Results

The pleura was the most common metastatic site (54.3%). In primary tumors, ER, PR, and HER2 positivity rates were 87%, 63%, and 21%, respectively, whereas in metastatic tissues they were 69.6%, 45.7%, and 25.6%. ER loss was observed in 17.4% of cases, with no gain detected. PR loss occurred in 23.9% and gain in 6.5%, while HER2 loss and gain were observed in 7.0% and 11.6% of cases, respectively. Univariate analysis identified pleural metastasis (HR=3.442, p=0.017), ER negativity in metastatic tissue (HR=3.306, p=0.008), PR negativity in metastatic tissue (HR=2.793, p=0.037), and ER loss (HR=3.095, p=0.022) as adverse prognostic factors. In multivariate analysis, pleural metastasis (HR=4.424, p=0.009) and ER loss (HR=3.669, p=0.010) remained independent predictors of poor survival. No significant association was found between HER2 status and survival.

Conclusion

ER loss and pleural metastasis are independent adverse prognostic factors in thoracic metastases of breast cancer. These findings related to tumor biology, particularly receptor status changes between primary and metastatic tumors, may help guide personalized therapeutic approaches.

Schlagwörter

breast cancerthoracic metastasesreceptor statusestrogen receptorprogesterone receptorHER2pleural metastasisreceptor lossprognostic factorssurvival

Zitieren

APA

SİLPAĞAR, A. E., Yardımcı, E. H., & Yıldırım, M. (2026). Comparison of Receptor Profiles Between Primary Tumors and Isolated Thoracic Metastasesin Breast Cancer. Revista do Grupo de Estudos do Cancro do Pulmão. https://doi.org/10.82582/thorac.95

Vancouver

SİLPAĞAR AE, Yardımcı EH, Yıldırım M. Comparison of Receptor Profiles Between Primary Tumors and Isolated Thoracic Metastasesin Breast Cancer. Revista do Grupo de Estudos do Cancro do Pulmão. 2026. doi:10.82582/thorac.95

BibTeX
@article{SLPAAR2026,
  author = {SİLPAĞAR, Aybiyçe E. and Yardımcı, Eyüp Halit and Yıldırım, Mehmet},
  title = {Comparison of Receptor Profiles Between Primary Tumors and Isolated Thoracic Metastasesin Breast Cancer},
  journal = {Revista do Grupo de Estudos do Cancro do Pulmão},
  year = {2026},
  doi = {10.82582/thorac.95}
}
Kostenlos starten →